Shenyang Xingqi Pharmaceutical (300573.SZ): The first subject enrolled in the clinical trial of SQ-22031 eye drops for the treatment of moderate to severe dry eye syndrome stage II.
Xingqi Eye Medicine (300573.SZ) announced today that the company's research and development of SQ-22031 eye drops has completed the first subject enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the effectiveness and safety of SQ-22031 eye drops in the treatment of moderate to severe dry eye. The trial has officially entered Phase II clinical trials.
Shenyang Xingqi Pharmaceutical (300573.SZ) announced that the company's research and development of SQ-22031 eye drops has completed the enrollment of the first subject in a Phase II clinical trial to evaluate the effectiveness and safety of SQ-22031 eye drops in the treatment of moderate to severe dry eye in a multi-center, randomized, double-blind, placebo-controlled study.
According to the announcement, the Phase II study of SQ-22031 eye drops for dry eye is a multi-center, randomized, double-blind, placebo-controlled clinical study. The aim is to evaluate the effectiveness and safety of SQ-22031 eye drops in patients with moderate to severe dry eye, and to analyze its immunogenicity and its impact on changes in corneal nerve density.
Related Articles
Market badly hit! Wall Street begins to question the massive arms race, Apple Inc. (AAPL.US) becomes a "anti-AI" safe haven.
On December 9th, JXR (01951) spent 9.2077 million Hong Kong dollars to repurchase 3.802 million shares.
JL Mag Rare-Earth (06680): Some directors and senior executives collectively reduced their holdings of 1,621,500 company shares.
Market badly hit! Wall Street begins to question the massive arms race, Apple Inc. (AAPL.US) becomes a "anti-AI" safe haven.
On December 9th, JXR (01951) spent 9.2077 million Hong Kong dollars to repurchase 3.802 million shares.
JL Mag Rare-Earth (06680): Some directors and senior executives collectively reduced their holdings of 1,621,500 company shares.
RECOMMEND
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025
As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
08/12/2025
